## Abstract Because of the occurrence of different types of mutations, comprehensive genetic testing for Parkinson's disease (PD), dopa‐responsive dystonia (DRD), and myoclonus‐dystonia (M‐D) should include screening for small sequence changes and for large exonic rearrangements in disease‐associat
Multiplex ligation-dependent probe amplification assay for simultaneous detection of Parkinson's disease gene rearrangements
✍ Scribed by Oronzo Scarciolla; Francesco Brancati; Enza Maria Valente; Alessandro Ferraris; Maria Vittoria De Angelis; Stefano Valbonesi; Barbara Garavaglia; Antonino Uncini; Giandomenico Palka; Liborio Stuppia; Bruno Dallapiccola
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 254 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Parkinson's disease (PD) is a common disorder caused by degeneration of dopaminergic neurons in the substantia nigra and other brain areas. Mutations in several genes have been associated with both autosomal dominant PD and recessive early onset Parkinsonism (EOP). Genomic rearrangements such as deletions or multiplications of one or more exons represent a common mutational mechanism for most of these genes and are not detectable with routine mutation screening techniques. MLPA (Multiplex Ligation‐dependent Probe Amplification), is a cheap, simple, rapid, and sensitive tool to detect exon dosage alterations and specific point mutations in selected genes. We tested the recently developed PD‐MLPA assay by using 13 positive control samples carrying known mutations in SNCA, LRRK2, Parkin, PINK1, and DJ‐1 genes. We then applied this technique to screen 16 EOP patients who were then cross‐tested by quantitative PCR (qPCR). All the mutations present in the positive control samples were clearly detected by MLPA. Moreover, three novel Parkin rearrangements were identified among EOP patients and confirmed by qPCR. Only two samples generated false positive duplications of LRRK2 exon 1 and UCH‐L1 exon 9, respectively. These results show that PD‐MLPA assay can simultaneously and effectively detect rearrangements in most PD genes (SNCA, Parkin, PINK1, and DJ‐1) as well as the LRRK2 G2019S common mutation. Thus, the use of this novel platform can improve the analysis of such mutations, facilitating comprehensive genetic testing in PD and EOP. © 2007 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract __Background__: Multiplex ligation‐dependent probe amplification (MLPA) has been used to detect deletions and mutations of the α‐globin gene for diagnosis of α‐thalassemia. MLPA reaction products are usually separated and analyzed by high‐voltage capillary gel electrophoresis (CGE). The
## Communicated by John McVey The need to detect clinically significant segmental aneuploidies beyond the range of light microscopy demands the development of new cost-efficient, sensitive, and robust analytical techniques. Multiplex ligation-dependent probe amplification (MLPA) has already been sh
ATM gene alterations have been described in various lymphoproliferative malignancies suggesting that ATM contributes to lymphomagenesis. Using multiplex ligation-dependant probe amplification (MLPA), we screened 61 childhood lymphoid malignancies for ATM genomic deletion/duplication. Five samples we
## Abstract This study aims to perform gene diagnosis for nine patients with Duchenne/Becker muscular dystrophy (DMD/BMD) and their parents with multiplex ligation‐dependent probe amplification (MLPA), and to carry out prenatal gene diagnosis for one of them. Genomic DNA of the peripheral blood and